Heidelberg Materials: Defending the Capital Base, Not Growing It
Recalculated after the 2026 half-year report: ROIC 10.4% above WACC, EV/EBITDA 7.7x, fair value around €184. A cash-return stock, not a growth stock.
The 2026 half-year report of Heidelberg Materials contains two figures that sit uneasily side by side: the share lost 25.2% in the first half while the DAX gained 2.1%, and over the same period earnings per share rose from €3.85 to €4.19 [1]. The report names regulatory uncertainty around the carbon price as a major driver of the share-price decline. A few weeks after the balance-sheet date, the European Commission pushed exactly that risk four years further out [3].
This is the continuation of my June analysis, based on the half-year report for January to June 2026, published on 30 July [1]. Three things have changed since then: the share price has fallen further, the balance sheet has been stretched by acquisitions, and the single largest risk to the thesis has moved out of the valuation horizon.
Heidelberg Materials earns its cost of capital, with a ROIC of 10.4% against a WACC of around 7.5%, and it protects that spread with local monopolies that cannot be copied. Organically, however, the company does not grow: capex and depreciation cancel each other out, and all asset growth comes from acquisitions and currency effects. I therefore read the share as a cash-return stock, not a growth stock. With normalised net debt and minorities deducted, I arrive at a weighted fair value of around €184, which is 10.4% above the price of €166.90. That is enough for a position, not for an overweight. Rating: Accumulate.
“The market treats an asset-backed quality compounder like a pure cyclical, and in doing so overlooks intact pricing power and a decarbonisation option that is hard to replicate.”
What the first half of 2026 shows
The half-year was operationally weak, but the structure behind it is better than the headline. The first quarter suffered from weather and the energy-price shock after the Middle East escalation; the second quarter already turned positive [1].
| Metric (€m) | H1 2025 | H1 2026 | Change |
|---|---|---|---|
| Revenue | 10,398 | 10,580 | +1.7% |
| RCOBD | 1,930 | 1,901 | −1.5% |
| RCOBD margin | 18.6% | 18.0% | −59 bps |
| RCO | 1,282 | 1,249 | −2.6% |
| Operating result (EBIT) | 1,187 | 1,199 | +1.0% |
| Earnings per share | €3.85 | €4.19 | +€0.34 |
| RCO (Q2 only) | 1,048 | 1,086 | +3.6% |
The decisive point is in the last row: taken in isolation, the operating result grew by 3.6% in the second quarter, and by 4.9% on a like-for-like basis [1]. The report speaks of a “first noticeable recovery in demand in the second quarter”. The weakness in the half-year as a whole is a Q1 problem, not a trend.
Management nevertheless narrowed its full-year guidance: RCO is now expected between €3.40bn and €3.65bn, whereas the upper end previously stood at €3.75bn [1]. The ROIC guidance remains unchanged at “slightly above 10%”. Less noticed, but worth mentioning: the CO₂ guidance was also pulled back. Specific net emissions per tonne of cementitious material are now expected to be “roughly at the prior-year level” instead of the slight reduction previously guided; the cause is the first-time consolidation of Akçansa [1]. For a company whose bull case rests substantially on CO₂ leadership, this weighs more heavily than the footnote in the report suggests.
The mandatory criterion: ROIC above WACC
The first test for any compounder is whether it earns its cost of capital. Heidelberg passes it, with a moderate spread typical of capital-intensive heavy industry. ROIC stood at 10.4% in 2025, after 9.9% the year before [2].
I calculated the WACC from current inputs; the inputs are my own assumptions. Cost of equity via CAPM with a beta of 0.91, a risk-free rate of 3.0% (ten-year Bund) and a market risk premium of 5.25% gives roughly 7.7%. I set the after-tax cost of debt at about 3.0%. Weighted at market values, this yields a WACC of around 7.5%.
Heidelberg earns its cost of capital and creates value. The spread is solid but moderate: this is a good compounder, not an exceptional one. Anyone used to ROIC spreads of 20 points from the software sector needs to recalibrate expectations for a heavy-industry business.
The moat: local monopolies and reserves
Heidelberg's moat is physical and geographical, and therefore robust. Cement and aggregates have such an unfavourable weight-to-value ratio that transport beyond roughly 150 to 300 kilometres does not pay. Whoever owns the plant and the quarry in a region holds a local quasi-monopoly with structural pricing power.
The pricing power is not theoretical. For the Europe group area, the half-year report records that selling prices were raised in all group countries, despite declining sales volumes [1]. In North America, prices rose in almost all business lines. That the margin still gave up 59 basis points is due to war-driven energy prices and higher freight costs, not to weakening pricing ability.
The balance sheet, with the necessary seasonal caveat
A correction to my June analysis is due here. The 1.2x net debt cited there was the 2025 year-end figure [2], and year-end figures are the most flattering vantage point for a seasonal business. At the half-year mark, leverage stands at 1.66 [1].
| Date | Net debt | Dynamic leverage ratio |
|---|---|---|
| 30.06.2025 | €7.20bn | 1.56x |
| 31.12.2025 | €5.29bn | 1.20x |
| 30.06.2026 | €7.73bn | 1.66x |
The clean comparison is half-year to half-year: 1.56 to 1.66. A mild, acquisition-driven deterioration, not a balance-sheet problem. The fortress balance sheet holds, but it is a fortress with seasonal swings, and that belongs in every presentation of it.
| Balance-sheet item (30.06.2026) | Value | Context |
|---|---|---|
| Property, plant and equipment | €15.22bn | ~40% of total assets |
| Goodwill + intangibles | €9.88bn | ~53% of shareholders' equity |
| Cash and cash equivalents | €2.19bn | €12.47 per share |
| Total equity | €19.80bn | Equity ratio 51.7% |
| Book value per share | €106.00 | P/B 1.57 |
In the first half, goodwill rose by €574m, essentially from the full consolidation of Akçansa (€364m) and BURNCO (€72m) [1]. Goodwill and intangible assets have thereby risen to around 53% of shareholders' equity. The argument “asset-backed rather than goodwill from overpriced acquisitions” remains valid; the Maas deal was closed at 8.4x post-synergy. But with the current M&A cadence it carries less weight than it did in June.
The blind spot of the old analysis: organic growth is zero
Total assets grew 10.6% year on year, property, plant and equipment 8.7% [1]. That looks like vigorous expansion. The breakdown in the fixed-asset schedule tells a different story.
| Change in PP&E, H1 2026 | €m |
|---|---|
| Currency effects | +162 |
| Business combinations | +493 |
| Other additions (organic capex) | +618 |
| Depreciation | −620 |
| Impairments | −39 |
| Disposals | −25 |
| Organic balance | −66 |
The organic asset base is shrinking slightly [1]. Capex and depreciation are practically identical at around €1.3bn per year. All asset growth comes from acquisitions and exchange rates.
That is not a weakness but a sharpening of my thesis: Heidelberg is a cash-return compounder, not a growth compounder. Value is created not by the company getting bigger, but by it defending its capital base and returning the surplus with discipline. Anyone expecting an accelerating business here is reading the wrong stock.
This also implies a caveat regarding Strategy 2030: the target is 7 to 10% RCO growth per year [2]. From €3.4bn in 2025 to the guidance midpoint of €3,525m for 2026 is 3.7%, roughly half of the target range, of which about three percentage points are attributable to currency headwinds. Year one of the strategy is running without any buffer.
The CO₂ transition: the biggest risk shifts
This is the most important piece of news since the June analysis. On 18 July 2026 the European Commission presented a reform proposal for the EU ETS 1 [3]. The key point for cement producers: the annual reduction of free allocation for CBAM sectors is to be stretched by four years. Free allocation would thus run until 2038 instead of 2034 as previously envisaged.
In addition, allowances are to continue to be issued after 2039 to cover unavoidable process emissions; negative emissions are to be integrated and international credits made creditable [3].
The CO₂ tail risk thereby moves out of the valuation horizon of a five- to ten-year DCF. At the same time, the option value remains intact: whoever leads, as Heidelberg does with Brevik, Padeswood and the oxyfuel pilot in Mergelstetten, gains against less well-capitalised competitors if costs do rise after all. The caveat: this is a proposal. I do not expect the final directive before mid-2027.
It is notable that, according to the report, precisely this regulatory uncertainty was a major driver of the share-price decline in the first half. The share fell 25.2% from the start of the year while the DAX gained 2.1% [1]. The trigger for the discount has thus partly disappeared; the discount itself has not.
Valuation: the recalculation
At a price of €166.90 (closing price on 30 June 2026), market capitalisation stands at €29.4bn [4]. Adding net debt gives an enterprise value of around €37.2bn; against an expected RCOBD of about €4.85bn, that is an EV/EBITDA of 7.7. US peers trade at 14x to 18x [4].
I have revised the DCF in two respects compared with the June version. First, I use normalised net debt of around €7.0bn instead of the seasonally flattering year-end figure. This value takes into account the expected H2 cash inflow, the outstanding Maas Group acquisition of around one billion euros and the remaining tranche of the share buyback. Second, I deduct minority interests of €1.17bn, which after the full consolidation of Akçansa are too large to ignore [1].
Method: FCFA2S (free cash flow to all securities), five explicit years, then a Gordon terminal value, discounted at a WACC of 7.5%. Base cash flow: €2.1bn.
Bear case (20%)
~€139
- FCF growth 1%, terminal g 1%
- Persistent volume weakness in Europe
- Energy costs cannot be passed on
Base case (60%)
~€185
- FCF growth 3%, terminal g 2%
- Pricing power intact, disciplined allocation
- Implies EV/EBITDA 8.2x, a moderate re-rating
Bull case (20%)
~€227
- FCF growth 5%, terminal g 2.5%
- M&A leverage plus CCS monetisation
- European construction recovery from 2027
Probability-weighted, this gives a fair value of around €184, an upside of 10.4% against €166.90. That is markedly less than the €205 of the June version, and the difference is almost entirely explained by the two methodological corrections, not by a deterioration of the business.
Five inputs in this calculation are my own assumptions, not company disclosures: the WACC inputs (beta 0.91, risk-free rate 3.0%, market risk premium 5.25%, after-tax cost of debt 3.0%); normalised net debt of around €7.0bn; the base cash flow of €2.1bn; the scenario weights of 20/60/20; and the minority charge in the P/E bridge, which I set at around €180m below and cross-check conservatively at €200m. Anyone who sets one of these inputs differently shifts the fair value by a few euros, but not the classification as a moderately undervalued cash-return stock.
The 2026e P/E, derived from the lowered guidance
Heidelberg does not publish earnings-per-share guidance; it steers by RCO. The bridge from RCO to earnings per share can nevertheless be built cleanly from the half-year figures; the first half provides all the necessary ratios [1].
| Bridge RCO → earnings per share | H1 2026 (actual) | FY 2026e (guidance midpoint) |
|---|---|---|
| Result from current operations (RCO) | €1,249m | €3,525m |
| Additional ordinary result | −€50m | ~−€180m incl. ~−€100m Bukhtarma |
| Financial result | −€111m | ~−€225m |
| Profit before tax | €1,088m | ~€3,120m |
| Tax rate | 25.5% | 25.5% |
| less minority interests | −€72m | ~−€180m Akçansa consolidated only from 30.06. |
| Attributable to shareholders | €738m | ~€2,145m |
| Earnings per share (reported) | €4.19 | ~€12.2 |
| Earnings per share (adjusted) | — | ~€13.0 range €12.5–13.5 across the guidance |
With 175.4 million shares outstanding and a price of €166.90, this gives a 2026e P/E of around 12.8 on an adjusted basis (13.7 on a reported basis) [4]. The June version cited 13.6. The decline does not come from a better earnings expectation but from the share price having fallen since, which has more than offset the lowered guidance.
Two caveats belong here. First, the adjusted figure is my own derivation, not a company disclosure: it strips out the additional ordinary result, which in the first half included impairments of €47m and restructuring expenses of €28m [1]. Second, the minority position is the least certain item in the bridge. Akçansa was first consolidated only as of 30 June 2026, so the second half of the year will be burdened considerably more here than the first. A conservative calculation uses €200m and lands at adjusted earnings per share of around €12.9.
The hurdle rate of 15% annualised is not reached at €166.90: 10.4% price upside plus around 2.2% dividend yield and about 1.5% buyback yield add up to an expected total return of roughly 9 to 12% per year. That justifies a position, but not an aggressive overweight. Below €155 the calculation tips clearly back into positive territory.
Bull and bear case
- ROIC above WACC, proven and rising (9.9% → 10.4%) [2]
- CO₂ risk pushed out four years by the ETS reform proposal [3]
- Local monopolies and protected reserves as a non-replicable moat
- Q2 2026 with +4.9% like-for-like RCO growth: turnaround visible [1]
- EV/EBITDA 7.7x versus 14–18x for US peers [4]
- Organic asset growth at zero, growth only via M&A
- Strategy 2030 running at half speed in year one (+3.7% instead of 7–10%)
- Leverage of 1.66x above the company's own target, Maas deal still pending
- Goodwill risen to ~53% of equity
- ETS relief is a proposal; the final directive will not come before mid-2027
Conclusion
Heidelberg Materials remains a solid, asset-backed quality compounder with a local-monopoly moat, a proven return on capital above its cost of capital and a genuine CO₂ option. My recalculation based on the half-year report is more sober than the June version, not because the business is weaker, but because the old calculation photographed the balance sheet at its most flattering point and overlooked the minorities.
“Value is created not by this company getting bigger, but by it defending its capital base and returning the surplus with discipline.”
Rating: Accumulate. Fair value (weighted) around €184, equivalent to +10.4% against the price of €166.90. Add below €155, where the 15% hurdle becomes reachable again. The thesis is mean reversion plus cash-return compounding over a horizon of three to ten years: not a trend trade, but a stock for the patient. Next checkpoint: the quarterly statement on 4 November 2026.
All valuation calculations in this article deliberately rest on the closing price of 30 June 2026 (€166.90, market capitalisation €29.4bn), the balance-sheet date of the half-year report from which all fundamental data are taken [4]. This keeps price and data basis on the same date.
For context as of today: on 27 August 2026 the share traded at €168.30, market capitalisation stood at €29.9bn and the share count at 175.4 million [4]. Against the weighted fair value of €184, that is an upside of 9.3% instead of the 10.4% at the June date. It changes nothing about the conclusion: Gate G3 remains unmet, and the add-on threshold of €155 stands.
Adjusted 2026e earnings per share are derived above in the valuation chapter (around €13.0, P/E ~12.8). The sale of Bukhtarma will lead to an expected loss of around €100m in H2 2026 and is included in the reported figure, not in the adjusted one [1].
Update log
- 05.09.2026 — Editorial revision to house style, list of sources added; figures and valuation unchanged.
- 04.09.2026 — Correction round: 2026e P/E derived from guidance (adjusted earnings per share around €13.0, P/E around 12.8), price as of 27.08.2026 (€168.30, upside 9.3%) added for context, withdrawal of the CO₂ guidance included. Price basis of the valuation remains 30.06.2026.
- 23.08.2026 — First publication of this update based on the 2026 half-year financial report; replaces the June analysis (fair value €205, P/E 13.6, leverage 1.2x).
Sources
- Heidelberg Materials AG, Half-Year Financial Report January to June 2026, Heidelberg, published 30.07.2026. Consolidated income statement, balance sheet as of 30.06.2026, fixed-asset schedule, net debt and leverage, acquisitions (Akçansa, BURNCO, Maas), 2026 guidance (RCO, ROIC, CO₂), share-price performance in the first half, Bukhtarma. → https://www.heidelbergmaterials.com/system/files/2026-07/Heidelberg_Materials_Half-Year%20Financial%20Report_2026.pdf
- Heidelberg Materials AG, Annual and Sustainability Report 2025, Heidelberg, March 2026. ROIC 2025 (10.4%) and 2024 (9.9%), net debt and leverage as of 31.12.2025, RCO 2025, Strategy 2030 targets. → https://www.heidelbergmaterials.com/system/files/2026-03/HM_GNB25_de.pdf
- European Commission, Proposal for the revision of the EU ETS Directive (ETS review) and Electrification Action Plan, press release IP/26/1596, Brussels, July 2026. Extension of the phase-out of free allocation for CBAM sectors to 2038, issuance of allowances after 2039 for process emissions, integration of negative emissions. → https://ec.europa.eu/commission/presscorner/detail/en/ip_26_1596
- Market data (XETRA closing prices, stockanalysis.com): price €166.90 on 30.06.2026 with market capitalisation €29.4bn; price €168.30 on 27.08.2026 with market capitalisation €29.9bn and 175.4 million shares; EV/EBITDA of US peers 14–18x.